Forming next-generation antibody–nanoparticle conjugates through the oriented installation of non-engineered antibody fragments

Abstract

Enabling oriented installation of non-engineered antibody fragments on nanoparticle surfaces to create next-generation antibody–nanoparticle conjugates.

Bioconjugation with Maleimides: A Useful Tool for Chemical Biology

“…[84] The DBPD platform has been considerably explored in the generation of ADCs, [85] antibody conjugates, [19,86,87] antibody directed photosensitizers, [84,88] protein-protein conjugates [89] and targeted nanotherapeutics. [90] AD BPD reagent incorporating a terminal alkyne and cyclooctyne probe was used to accomplish complete rebridging of Trastuzumab (4:1 ratio of PD-to-antibody). Both click probesw ere sequentially functionalized with Dox-N 3 and PEG 20000 -N 3 yielding an ADC with unaltered binding, internalizing andc ytotoxicp roperties.…”

“…DBPDs also contributed to the development of antibody-targeted nanomedicines (Scheme 26), as they enablep recise attachment of targeting antibodies onto nanoparticles urfaces. [90] In the field of oncology,c ontrolled surfacef unctionalization has been of key-importance in the design of severala ctively targeted nanocarriers. [96][97][98] As drug delivery vehicles, nanoparticles offer improved pharmacokinetics and safety profiles, being already approved for clinicalu se [99] (among other examples in clinicaltrials pipeline).…”

A Review of Nanotechnology for Targeted Anti-schistosomal Therapy

“…The bioconjugation of antibodies with nanoparticles to generate a unique product which is composed of both the properties of the antibodies and nanoparticles can take place by adsorption process that is, at the isoelectrical point of the antibody through electrostatic interaction (Arruebo et al, 2009;Greene et al, 2018). More so, the conjugation can take place by direct covalent bonding between the surface of the antibody and the nanoparticles (that is, coupling of the antibodies to nanoparticles by free carboxyl or amine functionalities on aspartic/glutamic acid or lysine residues or by thio-maleimide reaction) (Arruebo et al, 2009).…”

“…Another means by which the bioconjugation of the antibodies to the nanoparticles can be achieved is through the use of adapter molecules that is, bio-recognitions like streptavidin and biotin, which usually involves the formation of the complex. Greene et al (2018), developed a novel approach for the site-specific conjugation of nanoparticulate systems which promotes the uniform and outward projection of paratopes for utmost target interaction. They demonstrated a successful re-bridging of the inter-chain Mourão et al, 2005 disulfide linkage with a heterobifunctional linker and successive coupling to nanoparticles bearing complementary azide moieties in TRAZ F(ab) model.…”

Therapeutic lipid-coated hybrid nanoparticles against bacterial infections

“…antibodies) has the potential to signicantly enhance delivery efficiency. [152][153][154] A key concept in this active targeting strategy for infections is that the pathogens and the LCHNPs tend to accumulate in the same phagocytes, which could be exemplied by the current interest in antibody nanoparticle conjugates (ANCs). 155,156 ANCs represent a relatively new approach that builds on the success and potential of both antibody antibiotic conjugates (AACs) and nano-technological delivery systems.…”